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Abnormalities of age-related T cell
senescence in Parkinson’s disease
C. H. Williams-Gray1* , R. S. Wijeyekoon1, K. M. Scott1, S. Hayat1, R. A. Barker1 and J. L. Jones2
Abstract
Background: A wealth of evidence implicates both central and peripheral immune changes as contributing to the
pathogenesis of Parkinson’s disease (PD). It is critical to better understand this aspect of PD given that it is a
tractable target for disease-modifying therapy. Age-related changes are known to occur in the immune system
(immunosenescence) and might be of particular relevance in PD given that its prevalence rises with increasing age.
We therefore sought to investigate this with respect to T cell replicative senescence, a key immune component of
human ageing.
Methods: Peripheral blood mononuclear cells were extracted from blood samples from 41 patients with mild PD
(Hoehn and Yahr stages 1–2, mean (SD) disease duration 4.3 (1.2) years) and 41 age- and gender-matched controls.
Immunophenotyping was performed with flow cytometry using markers of T lymphocyte activation and
senescence (CD3, CD4, CD8, HLA-DR, CD38, CD28, CCR7, CD45RA, CD57, CD31). Cytomegalovirus (CMV) serology
was measured given its proposed relevance in driving T cell senescence.
Results: Markers of replicative senescence in the CD8+ population were strikingly reduced in PD cases versus
controls (reduced CD57 expression (p = 0.005), reduced percentage of ‘late differentiated’ CD57loCD28hi cells
(p = 0.007) and ‘TEMRA’ cells (p = 0.042)), whilst expression of activation markers (CD28) was increased (p = 0.005).
This was not driven by differences in CMV seropositivity. No significant changes were observed in the CD4
population.
Conclusions: This study demonstrates for the first time that the peripheral immune profile in PD is distinctly
atypical for an older population, with a lack of the CD8+ T cell replicative senescence which characterises normal
ageing. This suggests that ‘abnormal’ immune ageing may contribute to the development of PD, and markers of T
cell senescence warrant further investigation as potential biomarkers in this condition.
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Background
There is abundant evidence implicating a role for inflam-
mation and immune activation in Parkinson’s disease.
Neuroinflammatory changes including microglial activation
and increased concentrations of pro-inflammatory cyto-
kines are well described in PD postmortem brain [1, 2], and
microglial activation can be observed in vivo even in the
early stages of the disease using [11C]PK-11195 PET neuro-
imaging [3–5]. Inflammatory cytokines including IL-6 and
IL-8 are elevated in the cerebrospinal fluid (CSF) in PD
compared in controls [6, 7], and immune alterations have
been reported in peripheral blood including changes in
monocyte [8] and lymphocyte subsets in PD [9, 10], which
may be driven by a specific immune response to alpha
synuclein [11]. Whilst such immune and inflammatory
changes in PD might be, at least in part, secondary phe-
nomena, immune manipulation in animal models of PD
has been shown to alter disease susceptibility and severity
[12, 13], suggesting that immune changes may also be a
primary contributing factor to disease development. This is
supported by the now well-established genetic association
between the human leucocyte antigen (HLA) locus, the key
genetic susceptibility factor in disorders involving patho-
genic adaptive immune responses, and PD risk [14, 15].
Furthermore, our own recent data has shown that a
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pro-inflammatory cytokine profile in the serum in early PD
has prognostic significance, being associated with more
cognitive dysfunction and faster motor progression over
36 months of prospective follow-up in a large incident PD
cohort [16].
Given that PD is a condition which becomes increas-
ingly prevalent with age, the relevance of age-related
immune dysregulation (known as immunosenescence)
in this disorder warrants further investigation. One of
the hallmarks of immunosenescence is the loss of
naïve T cells, especially CD8+ cells, and the reciprocal
accumulation of memory cells, particularly terminally
differentiated effector CD8+ cells (TEMRAs), as a
result of age-related thymic involution and repeated
exposure to pathogens [17–19]. In vitro, progression
of CD8 T cells to a senescent state is characterised by
the loss of surface expression of the co-stimulatory
molecule CD28 and expression of CD57 [17, 20]. In
vivo, both TEMRA and CD28loCD57hi CD8+ cells are
increased in frequency in patients with chronic infec-
tions, e.g. HIV, as well as in older age [21–23]. Indeed,
accumulation of late differentiated CD8 cells has been
proposed to be a major characteristic of an ‘immune
risk profile’ in patents > 85 years which is associated
with higher mortality [18, 24]. Infection with cyto-
megalovirus (CMV) has been proposed as the key
pathogenic driver of this senescent CD8 subset [18],
with T cell receptor (TCR) restricted, CMV-specific T
cells comprising a large proportion of the CD8 T cells
in the elderly [25, 26]. Within the CD4 population,
similar phenotypic changes occur with repeated anti-
genic stimulation, but late differentiated CD4 cells
accumulate at a much lower frequency [27]. Loss of
thymic T cell production can also be measured in the
CD4 pool as a loss of CD4+ recent thymic emigrants
(RTEs), CD4+ naïve cells that co-express CD31 [19].
The functional impact of CD8+ T cell replicative
senescence is an overall impairment of the adaptive
immune response, with a consequent reduction in the
ability to fight novel infections and impairment in re-
sponses to vaccinations in the elderly [17]. The impact
of CD8+ cell senescence on the development and
progression of PD is unknown. Such changes may
reduce responses to disease-related antigens such as
misfolded alpha synuclein, thus limiting clearance of
toxic proteins and potentially contributing to PD.
Alternatively, they may be protective through reducing
the capacity of the immune system to become acti-
vated, hence limiting an important driver of central
neuroinflammation [28]. Here, we sought to answer
this question by investigating whether there was an as-
sociation between an immunosenescent T cell pheno-
type and PD and to determine the relevance of CMV
infection to this.
Methods
Subjects
Patients with early-stage PD (Hoehn and Yahr stage ≤ 2,
no dementia) were recruited from the Parkinson’s Dis-
ease Research Clinic at the John Van Geest Centre for
Brain Repair in Cambridge. All patients met the UKPDS
Brain Bank criteria for the diagnosis of PD [29] and were
aged between 55 and 80. Controls without neurological
disease were recruited from the NIHR Cambridge BioR-
esource. MAPT (microtubule-associated protein tau)
H1/H2 genotypes were available for all subjects. Con-
trols were age-, sex- and MAPT genotype-matched to
patients. Exclusion criteria included current infections,
chronic inflammatory or autoimmune disorders, vaccin-
ation within the past 3 weeks, surgery within the past
month, and recent use of immunosuppressive therapy
(< 1 year), oral or intravenous steroids (< 3 months),
non-steroidal anti-inflammatories (< 2 weeks) or as-
pirin > 75 mg (< 2 weeks). Control subjects had no
history of neurological disease, no self-reported memory
problems and no depression. PD cases underwent full clin-
ical assessment including medical history and comorbidities,
the Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS), Hoehn and Yahr Stage,
Addenbrooke’s Cognitive-Examination-Revised (ACE-R),
assessment of semantic fluency (animal naming in 90 s) and
pentagon copying and the Beck Depression Inventory.
Levodopa equivalent daily doses were calculated [30]. Cases
were stratified in terms of prognosis using factors
identified in our previous CamPaIGN study: they were
classified as high dementia risk if they carried the
MAPT (microtubule-associated protein tau) H1/H1
genotype and performed poorly on tests of semantic
fluency (< 20 animals in 90 s) and/or pentagon copy-
ing (< 2/2), intermediate risk if they carried one of
these factors and low risk if they carried no risk factors [31].
Sample processing
Up to 50 ml of venous blood was collected from each
participant in a combination of lithium heparin tubes for
peripheral blood mononuclear cell (PBMC) isolation,
plain tubes for serum separation and ethylenediamine-
tetraacetic acid (EDTA) tubes for measurement of full
blood count and differential count. Samples for
patient-control pairs were collected on the same day (9–
11 am) and processed in parallel to minimise inter-assay
variability. Plain tubes were left to clot for 15 min before
centrifugation at 2000 rpm and removal of serum, which
was stored at − 80 °C prior to subsequent analysis for
CMV IgG using a LIAISON® CMV IgG II chemilumines-
cent immunoassay (DiaSorin, Italy). PBMCs were sepa-
rated by centrifugation over a Ficoll gradient and
washed and divided into aliquots for immunophenotyp-
ing and cell separation into T cell subsets.
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PBMCs for phenotyping were blocked with 2%
mouse serum prior to labelling with two panels of
fluorochrome-conjugated monoclonal antibodies to T
cell surface markers of interest [panel 1: CD3(FITC),
CD4(PECy5), CD8(APCCy7), HLA-DR(V500), CD38(PE);
panel 2: CD3(APC), CD4(V500), CD8(APCCy7),
CD28(PECy7), CCR7(FITC), CD45RA(PECy5), CD57(PE),
CD31(V450), BD Biosciences). Cells were fixed with 2%
paraformaldehyde. Flow cytometry was performed on a
BD Biosciences FACS CantoII with BD FACS Diva soft-
ware. Isotype-matched mouse monoclonal antibodies
were used where appropriate to exclude non-specific anti-
body binding. Unstained lymphocytes were also used as
negative controls.
Data analysis
Immunophenotyping data was analysed using Flowjo. Lym-
phocytes were gated using forward scatter and side scatter,
and single cells were identified using forward-scatter area
versus width. CD4 and CD8 subsets were identified by gat-
ing on CD3-high CD4-high and CD3-high CD8-high cells
respectively. Naïve, central memory, effector memory
and terminally differentiated memory CD45RA+ cells
(TEMRA) were identified based on CCR7 and CD45RA
expression [19]. Senescent ‘late differentiated’ cells were
defined as CD28-low CD57-high cells within the CD8
population. RTEs were identified as CD31+ cells within
the CD4 naïve (CCR7+CD45RA+) population. Expres-
sion of markers of activation (CD28, CD38, HLA-DR)
and senescence (CD57) were quantified within CD4+
and CD8+ populations as the ratio of median fluores-
cence intensity in labelled versus unlabelled lympho-
cytes (MFI ratio), to allow for variations in voltage
between samples.
The primary statistical analyses involved comparison of T
cell subsets (as a percentage of lymphocytes) and MFI
ratios for relevant markers in PD cases versus matched
controls using paired t tests. CMV positivity in patients
versus controls was compared using chi-square tests, and
analyses of variance (ANOVA), including age as a covariate,
were used for patient-control comparisons of T cell markers
in CMV-positive and CMV-negative subgroups. Relation-
ships between relevant markers and clinical measures of
motor and cognitive functions were explored using Pear-
son’s correlations. Statistical analysis was performed using
GraphPad Prism version 6.0 and SPSS version 25 (IBM).
Results
Forty-one patients with PD and 41 age/gender-matched
controls were recruited. Demographic and clinical char-
acteristics of the subjects and CMV status are shown in
Table 1. Nine PD cases were designated high dementia
risk, 18 were low risk and 14 were intermediate risk.
Analysis of full blood and differential counts in n = 20
PD and 20 controls revealed lower total lymphocyte
counts in PD cases than controls (1.4 (0.4) versus 1.9
(0.6) × 109/L; p = 0.01) with no significant differences in
monocyte or neutrophil numbers. Flow cytometric data
from the full cohort indicated no difference in the
CD4:CD8 ratio between PD cases and controls [3.8 (2.3)
versus 3.3 (3.0); p > 0.05].
However, there was a reduction in the number and
proportion of CD28loCD57hiCD8+ T cells in individuals
with PD compared to controls, along with a marginally
significant reduction in CD8+ TEMRA cells and accom-
panying small increase in CD8+ central memory cells
(Table 2 and Fig. 1a, b). Expression of the activation
markers CD38 and HLA-DR on CD8+ T cells was not
different between patients and controls, but expression
of CD57 was reduced and expression of CD28 was in-
creased in PD patients (Table 3; Fig. 1c), in keeping with
the CD8+ subset data (Table 3; Fig. 1c). No differences
Table 1 Demographic and clinical characteristics of subjects
Variable PD (n = 41) Controls
(n = 41)
p
Age (years) 68.4 (6.3) 68.1 (5.6) 0.85
Gender (% male) 68.3 68.3 1.0
Disease duration (years) 4.3 (1.2)
MDS-UPDRS motor score 34.9 (12.4)
ACE-R 93.0 (8.3)
Levodopa equivalent daily dose (mg) 591.5 (292.9)
CMV IgG (% positive) 46.3 61.0 0.18
Values shown are mean (SD) unless otherwise stated. Continuous variables
compared using Student’s t tests and categorical variables compared using
chi-square tests or Fisher’s exact test as appropriate
MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating
Scale, ACE-R Addenbrooke’s Cognitive Examination-Revised
Table 2 T lymphocyte subsets
Subset (% of lymphocytes) PD Control p
CD8 Naïve 3.4 (2.3) 3.1 (2.4) 0.511
Central memory 1.5 (1.2) 1.1 (0.9) 0.015
Effector memory 6.6 (3.6) 7.2 (5.0) 0.516
TEMRA 6.2 (6.3) 9.3 (7.9) 0.042
CD28lo57hi 5.3 (4.5) 9.0 (8.0) 0.007*
CD4 Naïve 17.5 (9.0) 16.0 (8.2) 0.406
Central memory 18.0 (6.7) 15.8 (6.7) 0.052
Effector memory 14.2 (6.5) 12.8 (6.4) 0.245
TEMRA 2.1 (2.4) 2.0 (2.3) 0.747
RTE 2.2 (3.3) 2.1 (2.2) 0.827
T lymphocyte subsets are expressed as a percentage of the
lymphocyte population.
TEMRA terminally differentiated effector memory CD45RA+ve cells, RTE recent
thymic emigrants
*p value (from paired t test) which remains < 0.05 following Bonferroni
correction for multiple testing
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were identified in the CD4+ T cell pool between patients
and controls.
For cell subsets/markers reaching significance (p < 0.05),
ANOVA were performed to assess the effect of dementia
risk group on the observed case-control differences (with
‘case-control status’ and ‘risk subgroup’ included as fixed
factors and age and gender as covariates). Main effects of
‘case-control status’ were confirmed for the markers previ-
ously identified, but there was no interaction with risk
subgroup. Amongst the PD cases, no significant correla-
tions were found between T cell subset percentages, or
surface markers of activation and senescence, and either
clinical measures of motor and cognitive function or
equivalent daily levodopa dose.
CMV IgG seropositivity was not significantly different
between PD cases (19/41) and controls (25/41) (p = 0.18).
Nonetheless, given the previously described association
between CMV exposure and CD8 immunosenescence,
we explored this relationship further. As anticipated, CD8+
senescence markers were elevated in CMV-positive versus
Fig. 1 CD8 immunophenotyping in PD cases (n = 41) versus age-matched controls (n = 41). a Following gating of the lymphocyte and singlet
populations, CD8 cells were gated on the basis of high CD3 and CD8 staining, and the CD28loCD57hi subset was identified as a discrete
population of CD8+ cells using 5% contour plots. Quadrant gates were used to divide the CD8 population into naïve, central memory, effector
memory and TEMRA (terminally differentiated effector memory CD45RA+ve cells) subsets on pseudocolour dot plots. b Individual-level data for
CD8 cell subsets (shown as percentage of lymphocytes). c Individual-level data for surface marker expression in CD8 T cells (median fluorescence
intensity (MFI) ratio versus unstained lymphocytes). Horizontal lines denote means; *p < 0.05, **p < 0.01 in paired t tests
Table 3 T cell surface marker expression
Marker PD Control p
CD8 CD28 188.6 (102.5) 131.5 (88.3) 0.005*
CD38 1.9 (1.2) 2.3 (1.6) 0.117
HLA-DR 1.8 (0.4) 2.0 (0.6) 0.055
CD57 38.2 (69.9) 161.0 (261.7) 0.005*
CD4 CD28 334.6 (97.3) 299.8 (89.1) 0.067
CD38 6.1 (3.0) 7.1 (4.0) 0.057
HLA-DR 1.1 (0.2) 1.2 (0.2) 0.413
CD57 1.8 (1.5) 2.0 (1.3) 0.493
Values shown are mean (SD) ratio of median fluorescent intensity versus
unstained lymphocytes (MFI ratio)
*p value which remains < 0.05 following Bonferroni correction for
multiple testing
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CMV-negative subjects overall, including CD57 expression
(ANOVA with age as covariate, F = 4.66, p = 0.03),
CD28loCD57hi cells (% of lymphocytes, F = 18.75, p < 0.001)
and TEMRA cells (% of lymphocytes, F = 12.71, p = 0.001).
However, this effect was more apparent for controls than
for PD patients, with significantly higher CD57 ex-
pression (p = 0.017) and CD28loCD57hi cells (% of
lymphocytes, p = 0.028) in controls versus PD cases in
the CMV-positive group (Fig. 2).
Discussion
This study demonstrates for the first time that the per-
ipheral immune profile in PD is distinctly atypical for a
more elderly population, with a lack of the CD8+ T cell
replicative senescence which characterises normal age-
ing. Although other authors have reported phenotypic
alterations in the T lymphocyte population in PD, these
alterations have mainly been restricted to CD4+ cell sub-
sets with conflicting findings [9, 32, 33] and we found
no changes in the CD4+ T cell pool in this study. No
previous studies have specifically explored markers of T
cell replicative senescence in PD. CMV infection has
been strongly implicated in CD8+ replicative senescence
[18], but this does not appear to be confounding our ob-
servations, with similar levels of CMV IgG positivity in
both patient and control groups. Instead, the senescent
shift typically induced by chronic latent CMV infection
is not observed in this PD cohort. This is an intriguing
finding, raising the possibility that there are inherent
differences in the adaptive immune response to chronic
viral infections in PD. We hypothesise that these differ-
ences may contribute to a more active T cell-mediated
immune response to PD-relevant antigens such as alpha
synuclein, leading in turn to an exaggerated neuroin-
flammatory response which may contribute to the
neuropathology of PD.
In keeping with this hypothesis, there is well-established
evidence from genetic studies of an immune-mediated
susceptibility to PD, with association between the HLA
locus, which is critical in antigen recognition, and PD risk
[14, 34], as well as more widespread genomic associations
in loci affecting T cell regulation and function [35, 36].
Furthermore, specific T cell responses to epitopes of alpha
synuclein have recently been described at a higher fre-
quency in PD patients than controls by Sulzer and col-
leagues [11] and were closely associated with possession
of known PD risk alleles at the HLA locus. In addition,
alpha synuclein peptides have been shown to bind to these
HLA ‘risk variant’ molecules in vitro, thus revealing a
potential functional mechanism through which the
well-described HLA association may contribute to the
development of PD. Whilst the authors of this work
highlighted the importance of the Th2-type CD4+
cell-mediated response observed in their experiments,
they also found evidence of a significant CD8+-mediated
response when stimulating cells with shorter alpha synu-
clein peptides, and in fact, the strongest association be-
tween alpha synuclein-specific T cell responses and HLA
was seen for the MHC class I allele HLA A*11.02, thus
underlining the relevance of the CD8 (MHC class 1 re-
stricted) response [11]. The latter would be in keeping
with our observations that PD-associated immunophe-
notypic changes in our cohort were within the CD8+
population. Other authors have similarly shown an
elevated CD8+ T cell response to alpha synuclein
peptides and herpes simplex virus peptides in PD
versus controls [37].
The mechanism by which alterations in peripheral
CD8+ T cell function and CNS pathology interact in PD
is still not fully elucidated. However, it is now clear that
there is an abundance of T lymphocytes within the men-
inges which keep the brain under immune surveillance
and which drain, together with CNS antigens, via the
CNS lymphatic system to the local lymph nodes [38].
These meningeal T cells may be activated by ‘alarm
signals’ released into the CSF by degenerating CNS neu-
rones [39] and in turn produce inflammatory cytokines
which can diffuse into the brain parenchyma and lead to
further activation of already ‘primed’ microglia [40] and/
or impact directly on neuronal function [41].
Fig. 2 CD8+ senescence markers in CMV-positive versus CMV-negative subjects. The figure shows CD57 expression on CD8+ lymphocytes
(median fluorescence intensity (MFI) ratio versus unstained lymphocytes), CD8+ CD28loCD57hi cells (percentage of lymphocytes) and TEMRA cells
(percentage of lymphocytes) in PD versus age-matched controls stratified by CMV seropositivity. Horizontal lines denote means; *p < 0.05
and ***p≤ 0.001
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Furthermore, the presence of CD8+ cells within the
brain parenchyma in postmortem tissue from PD pa-
tients raises the possibility of direct interaction with
neurones presenting relevant antigen in the context of
MHC class 1, with consequent cytotoxic effects [12].
In this study, we adopted a hypothesis-driven ap-
proach and so restricted our T cell phenotyping to
specifically explore cell subsets and markers relevant to
activation and replicative senescence. A consequent limi-
tation of the study is that we were not able to fully char-
acterise the T cell population in our cohort, nor assess
changes in T regulatory cells, which have been reported
to be reduced in both number, and functional ability to
suppress effector T cells in PD patients [9]. Another po-
tential limitation of our study is that the majority of our
patients were taking dopaminergic medication, which
has been implicated as a potential confounding factor in
alterations in lymphocyte populations in PD cohorts
[33]. In particular, in vitro data indicates that dopamine
is an activator of effector T cells and an inhibitor of
regulatory T cells [42]. However, studies specifically
comparing medicated and unmedicated PD patients have
found no relationship between levodopa treatment and
changes in T cell subsets [32]. Similarly, we found no as-
sociations between T cell phenotypes or surface marker
expression and equivalent levodopa dose in our patient
cohort suggesting that medication was not a significant
factor driving the observed reduction in markers of CD8
replicative senescence.
Although we found clear differences in T cell senes-
cence markers between patient and control groups, we
were not able to demonstrate a relationship between
these markers and dementia risk status or clinical mea-
sures of disease severity within the PD group. This may
be because the observed immunophenotypic differences
are most relevant to the earliest stages of the disease,
impacting on susceptibility but not on the rate of pro-
gression. However, the power of our study to detect
differences between dementia risk subgroups was likely
suboptimal given the size of our cohort. In terms of
measures of disease severity, the spread across the group
was relatively minimal (Table 1) which consequently lim-
ited our ability to explore correlations with disease stage.
Further studies exploring these markers both across a
range of disease stages, and longitudinally in individual
patients, would be of interest.
Conclusions
Our data reveal that there is a reduction in age-associated
replicative senescence of CD8+ T cells in PD patients
compared with strictly age-matched controls. Hence,
whilst immunosenescence may be detrimental in terms of
increased susceptibility to infections and cancers with in-
creasing age, it may provide a degree of protection against
age-related neurodegenerative disorders such as PD,
through limiting immune activation to aberrant peptides
associated with these diseases. On a practical level, this
work suggests that the CD8+ CD28loCD57hi immunophe-
notype warrants further evaluation as a biomarker in PD,
which could be relevant for patient stratification for clin-
ical trials of immunomodulating therapies. Furthermore,
whilst immunomodulatory strategies targeting the CD4
population are being developed [43], the CD8 population
may also warrant consideration as a target for immune
therapies in PD.
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